Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about PLRX, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Bexotegrast (PLN-74809) | Idiopathic Pulmonary Fibrosis | Phase 2 · NCT06097260 | Terminated |
| AlphaVbeta1/8 Inhibitor PLN-101095 | Advanced or Metastatic Solid Tumor | Phase 1 · NCT06270706 | Recruiting |
| Fluorine F 18 FP-R01-MG-F2 | Idiopathic Pulmonary Fibrosis | Early Phase 1 · NCT03183570 | Completed |
Also used in these trials (approved or third-party drugs, not PLRX's own candidates): Pembrolizumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
PLRX holds $175.2M in cash and short-term investments (as of Jun 30, 2026) and burns about $16M/quarter from operations, an estimated runway of 32.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 25 · Moderate
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when PLRX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT, LLC | 5%+ holder (13D) | 5,859,044 | 9.45% | 2025-03-03 |
| ADAR1 Capital Management, LLC | Institution (13G, 5%+) | 5,509,724 | 8.89% | 2026-06-30 |
| Bernard Coulie President and CEO, Director · +3.18M options |
Insider | 914,918 | 1.48% | 2026-01-20 |
| Keith Lamont Cummings Chief Financial Officer · +992,495 options |
Insider | 297,214 | 0.48% | 2026-01-20 |
| Hans Hull Chief Business Officer · +80,300 options |
Insider | 265,693 | 0.43% | 2025-01-23 |
| Eric Lefebvre Chief Medical Officer · +91,300 options |
Insider | 240,224 | 0.39% | 2025-01-23 |
| Mike Ouimette General Counsel & Corp. Sec'y · +70,000 options |
Insider | 105,544 | 0.17% | 2025-01-23 |
| Lily Cheung Chief Human Resource Officer · +526,750 options |
Insider | 44,847 | 0.07% | 2026-01-20 |
| Minnie Kuo Chief Operating Officer · +545,200 options |
Insider | 37,806 | 0.06% | 2026-01-20 |
Share count 61,990,635 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PLRX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →